IMNN: R&D Day Highlights Potential for IMNN-001
On November 10, 2025, Imunon, Inc. (IMNN) held an R&D Day and provided updates on the latest data for IMNN-001 along with the ongoing OVATION...
153 Views
IMNN: OVATION 2 Translational Data Shows IMNN-001 Alters Tumor Microenvironment
On September 22, 2025, Imunon, Inc. (IMNN) announced the presentation of new translational data from the company's Phase 2 OVATION 2 trial of...
189 Views
IMNN: First Patient Dosed in Phase 3 OVATION 3 Trial
On August 5, 2025, Imunon, Inc. (IMNN) announced financial results for the second quarter of 2025 and provided a business update. The company...
144 Views
IMNN: Translational Data from OVATION 2 Presented
On June 18, 2025, Imunon, Inc. (IMNN) announced the presentation of positive translational data from the Phase 2 OVATION 2 study of IMNN-001 at...
378 Views
IMNN: Momentum Continues with Presentations at ASCO and ESMO Gynaecological Cancers
Imunon, Inc. (IMNN) has a very important June 2025 planned with multiple presentations at prestigious scientific conferences and the publication...
283 Views